Quantcast
Home > Quotes > APTO

Aptose Biosciences, Inc. Common Shares (APTO) Quote & Summary Data

APTO 
$1.96
*  
0.04
2%
Get APTO Alerts
*Delayed - data as of Nov. 14, 2018  -  Find a broker to begin trading APTO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    APTO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
7.75
Today's High / Low
$ 2.1099 / $ 1.8217
Share Volume
361,949
50 Day Avg. Daily Volume
234,231
Previous Close
$ 2
52 Week High / Low
$ 4.55 / $ 1.68
Market Cap
74,031,991
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.43

Intraday Chart

News for APTO

Shares Traded

Share Volume:
361,949
50 Day Avg. Daily Volume:
234,231

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.81

Trading Range

The current last sale of $1.96 is 16.67% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.1099 $ 4.55
 Low: $ 1.8217 $ 1.68

Company Description (as filed with the SEC)

Aptose is a science-driven biotechnology company advancing highly differentiated agents to treat unmet medical needs in life-threatening cancers, such as acute myeloid leukemia ("AML"), high-risk myelodysplastic syndromes ("MDS") and other hematologic malignancies. Based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, Aptose is building a pipeline of novel and targeted oncology therapies directed at dysregulated processes and signaling pathways in cancer cells, and this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. Our product pipeline includes cancer drug candidates that exert potent activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.  ... More ...  


Risk Grade

Where does APTO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.02
Open Date:
Nov. 14, 2018
Close Price:
$ 1.96
Close Date:
Nov. 14, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x